These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

408 related articles for article (PubMed ID: 25178936)

  • 1. Expression and clinical significance of Centrosomal protein 55 (CEP55) in human urinary bladder transitional cell carcinoma.
    Singh PK; Srivastava AK; Rath SK; Dalela D; Goel MM; Bhatt ML
    Immunobiology; 2015 Jan; 220(1):103-8. PubMed ID: 25178936
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Frequent expression of zinc-finger protein ZNF165 in human urinary bladder transitional cell carcinoma.
    Singh PK; Srivastava AK; Dalela D; Rath SK; Goel MM; Bhatt ML
    Immunobiology; 2015 Jan; 220(1):68-73. PubMed ID: 25214475
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of PDZ-binding kinase/T-LAK cell-originated protein kinase (PBK/TOPK) in human urinary bladder transitional cell carcinoma.
    Singh PK; Srivastava AK; Dalela D; Rath SK; Goel MM; Bhatt ML
    Immunobiology; 2014 Jun; 219(6):469-74. PubMed ID: 24629784
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Frequent expression of a novel cancer testis antigen, protein kinase human monopolar spindle 1 (hMps1/TTK) in human urinary bladder transitional cell carcinoma.
    Singh PK; Bhatt MLB; Singh P; Rath SK; Dalela D; Goel MM
    Drug Discov Ther; 2021 Sep; 15(4):204-209. PubMed ID: 34456216
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Altered mRNA expression of the Rb and p16 tumor suppressor genes and of CDK4 in transitional cell carcinomas of the urinary bladder associated with tumor progression.
    Quentin T; Henke C; Korabiowska M; Schlott T; Zimmerman B; Kunze E
    Anticancer Res; 2004; 24(2B):1011-23. PubMed ID: 15161057
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of CD147, BIGH3 and Stathmin and their potential role as diagnostic marker in patients with urothelial carcinoma of the bladder.
    Bhagirath D; Abrol N; Khan R; Sharma M; Seth A; Sharma A
    Clin Chim Acta; 2012 Oct; 413(19-20):1641-6. PubMed ID: 22626996
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of CEP55, PLK1 and FOXM1 expression in patients with bladder cancer in comparison with healthy individuals.
    Seyedabadi S; Saidijam M; Najafi R; Mousavi-Bahar SH; Jafari M; MohammadGanji S; Mahdavinezhad A
    Cancer Invest; 2018; 36(8):407-414. PubMed ID: 30277841
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression profile of cancer-testis genes in transitional cell carcinoma of the bladder.
    Yin B; Liu G; Wang XS; Zhang H; Song YS; Wu B
    Urol Oncol; 2012; 30(6):886-92. PubMed ID: 21396841
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Frequency of NY-ESO-1 and LAGE-1 expression in bladder cancer and evidence of a new NY-ESO-1 T-cell epitope in a patient with bladder cancer.
    Sharma P; Gnjatic S; Jungbluth AA; Williamson B; Herr H; Stockert E; Dalbagni G; Donat SM; Reuter VE; Santiago D; Chen YT; Bajorin DF; Old LJ
    Cancer Immun; 2003 Dec; 3():19. PubMed ID: 14680360
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation between messenger RNA expression and protein expression of immune checkpoint-associated molecules in bladder urothelial carcinoma: A retrospective study.
    Le Goux C; Damotte D; Vacher S; Sibony M; Delongchamps NB; Schnitzler A; Terris B; Zerbib M; Bieche I; Pignot G
    Urol Oncol; 2017 May; 35(5):257-263. PubMed ID: 28291636
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alteration of the vascular endothelial growth factor and angiopoietins-1 and -2 pathways in transitional cell carcinomas of the urinary bladder associated with tumor progression.
    Quentin T; Schlott T; Korabiowska M; Käthei N; Zöller G; Glaser F; Kunze E
    Anticancer Res; 2004; 24(5A):2745-56. PubMed ID: 15517881
    [TBL] [Abstract][Full Text] [Related]  

  • 12. microRNA expression profile in a large series of bladder tumors: identification of a 3-miRNA signature associated with aggressiveness of muscle-invasive bladder cancer.
    Pignot G; Cizeron-Clairac G; Vacher S; Susini A; Tozlu S; Vieillefond A; Zerbib M; Lidereau R; Debre B; Amsellem-Ouazana D; Bieche I
    Int J Cancer; 2013 Jun; 132(11):2479-91. PubMed ID: 23169479
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Urinary survivin mRNA expression and urinary nuclear matrix protein 22 BladderChek® and urine cytology in the detection of transitional cell carcinoma of the bladder.
    Al-Maghrebi M; Kehinde EO; Kapila K; Anim JT
    Med Princ Pract; 2012; 21(3):295-7. PubMed ID: 22236881
    [TBL] [Abstract][Full Text] [Related]  

  • 14. p15(INK4b) in bladder carcinomas: decreased expression in superficial tumours.
    Le Frère-Belda MA; Cappellen D; Daher A; Gil-Diez-de-Medina S; Besse F; Abbou CC; Thiery JP; Zafrani ES; Chopin DK; Radvanyi F
    Br J Cancer; 2001 Nov; 85(10):1515-21. PubMed ID: 11720438
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transient receptor potential vanilloid type 2 (TRPV2) expression in normal urothelium and in urothelial carcinoma of human bladder: correlation with the pathologic stage.
    Caprodossi S; Lucciarini R; Amantini C; Nabissi M; Canesin G; Ballarini P; Di Spilimbergo A; Cardarelli MA; Servi L; Mammana G; Santoni G
    Eur Urol; 2008 Sep; 54(3):612-20. PubMed ID: 17977643
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rsf-1/HBXAP overexpression is independent of gene amplification and is associated with poor outcome in patients with urinary bladder urothelial carcinoma.
    Liang PI; Wu LC; Sheu JJ; Wu TF; Shen KH; Wang YH; Wu WR; Shiue YL; Huang HY; Hsu HP; Chen YH; Chen LT; Li CF; Liao AC
    J Clin Pathol; 2012 Sep; 65(9):802-7. PubMed ID: 22685262
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In situ gene expression of urokinase-type plasminogen activator and its receptor in transitional cell carcinoma of the human bladder.
    Bhuvarahamurthy V; Schroeder J; Denkert C; Kristiansen G; Schnorr D; Loening SA; Jung K; Staack A
    Oncol Rep; 2004 Oct; 12(4):909-13. PubMed ID: 15375521
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of nucleophosmin/B23 mRNA expression with clinical outcome in patients with bladder carcinoma.
    Tsui KH; Cheng AJ; Chang Pe; Pan TL; Yung BY
    Urology; 2004 Oct; 64(4):839-44. PubMed ID: 15491744
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A prospective evaluation of the diagnostic and potential prognostic utility of urinary human telomerase reverse transcriptase mRNA in patients with bladder cancer.
    Bowles L; Bialkowska-Hobrzanska H; Bukala B; Nott L; Razvi H
    Can J Urol; 2004 Dec; 11(6):2438-44. PubMed ID: 15636669
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overexpression of caldesmon is associated with tumor progression in patients with primary non-muscle-invasive bladder cancer.
    Lee MS; Lee J; Kim JH; Kim WT; Kim WJ; Ahn H; Park J
    Oncotarget; 2015 Nov; 6(37):40370-84. PubMed ID: 26430961
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.